Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Nov / Deep Profiles for Personalized Medicine
Omics Analytical science Liquid biopsy Molecular Pathology

Deep Profiles

How small molecule enhancements revolutionize plasma proteomics

By Helen Bristow 11/22/2024 News 1 min read

Share

Researchers have demonstrated that adding small molecules to plasma can significantly expand the detection of low-abundance proteins, addressing a major challenge in plasma proteomics. The research, published in Nature Communications, reveals that small molecule-induced modulation of protein coronas on nanoparticles boosts proteome coverage, aiding biomarker discovery and disease monitoring.

Plasma proteomics often struggles with detecting low-abundance proteins because of the dominance of high-abundance ones like albumin, which comprise 85 percent of plasma protein mass. This study explored how small molecules, including phosphatidylcholine (PtdChos), glucose, and triglycerides, influence the protein corona – a layer of proteins adsorbed on nanoparticle surfaces. By modifying plasma samples with these molecules, researchers achieved an 8.25-fold increase in the number of proteins detected compared with plasma alone.

Using polystyrene nanoparticles, the team quantified 1,793 unique proteins through liquid chromatography-mass spectrometry (LC-MS/MS), far surpassing the 218 proteins detected in untreated plasma. Remarkably, PtdChos alone enabled the identification of 897 proteins, including low-abundance ones, by selectively reducing albumin and other high-abundance proteins in the corona.

The study also showed that the addition of PtdChos improved proteoform quantification by enriching proteins linked to diseases like cardiovascular and neurodegenerative disorders.

Molecular dynamics simulations further revealed that PtdChos interacts with albumin through hydrophobic interactions and hydrogen bonds, reducing its representation in the corona. This strategy eliminates the need for costly and labor-intensive albumin depletion kits, streamlining proteomics workflows.

The findings have broad implications for biomarker discovery and personalized medicine. By enabling deeper plasma proteome profiling, the approach could uncover novel biomarkers and improve early disease diagnosis. Future studies aim to validate the method across diverse patient cohorts, paving the way for its clinical adoption in precision diagnostics.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

More Articles by Helen Bristow

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.